Clinical Trials
14 trialsNCT05378763 2026-05-22
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
NCT07376382 2026-05-13
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT05615142 2026-05-11
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Sichuan University
Phase 1 Active not recruiting
NCT07379398 2026-04-29
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07550920 2026-04-24
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07530744 2026-04-15
Cronos
Elisabethinen Hospital
Phase NA Not yet recruiting
NCT00280189 2026-04-14
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
University of Pittsburgh
Suspended
NCT06865339 2026-04-13
TRIPL
Montefiore Medical Center
Phase 2 Recruiting
NCT07516015 2026-04-07
Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC
Nanjing Tianyinshan Hospital
Not yet recruiting
NCT03606070 2026-03-23
IMAHTEP
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Terminated
NCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT07388771 2026-03-19
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
Tongji Hospital
Recruiting
NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated